![Using a robot to perform mastectomies, a New Jersey surgeon sets off a firestorm over surgical outcomes How much rigor should be required when surgeons innovate? FDA's advisory asks for long-term cancer-related data](https://cdn.cancerletter.com/media/2019/04/da-vinci-robot2-web.jpg)
![Using a robot to perform mastectomies, a New Jersey surgeon sets off a firestorm over surgical outcomes How much rigor should be required when surgeons innovate? FDA's advisory asks for long-term cancer-related data](https://cdn.cancerletter.com/media/2019/04/da-vinci-robot2-web.jpg)
Cover Story
Free
Last August, Stephen A. Chagares, a breast surgeon, made an announcement that startled some of his colleagues at New Jersey’s Monmouth Medical Center. At internal meetings and in a press release, Chagares declared that he would perform a robotic mastectomy—a new and relatively untested minimally invasive surgical procedure. According to the press release, his first patient, Yvonne Zucco, 56, was being treated for stage IIa breast cancer.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Better oncology drug management could lead to improved outcomes, lower costs
- Tweaking the existing systems is not the answer to drug shortages